Insmed (NASDAQ: INSM) reported Q3 EPS of ($1.11), $0.02 better than the analyst estimate of ($1.13). Revenue for the quarter came in at $79.1 million versus the consensus estimate of $79.14 million.

GUIDANCE:

Insmed sees FY2023 revenue of $295-305 million, versus the consensus of $303.4 million.

For earnings history and earnings-related data on Insmed (INSM) click here.